NINOVATING TREATMENTS THROUGH

November 19, 2020

2020 Canaccord Genuity Virtual Medical Technologies & Diagnostics Forum

IMPORTANT CAUTIONARY STATEMENT

This presentation contains forward-looking statements. Investors are cautioned against placing undue reliance on these statements.

All statements relating to events or results that may occur in the future are forward-looking statements, including, without limitation, statements regarding the following:

- the regulatory pathway for our products, including our existing and planned investigative new drug application and pre-market approval requirements, the timing, design and success of our clinical trials and pursuit of biologic license applications ("BLAs") and other regulatory approvals for certain products;
- our expectations regarding our ability to continue marketing our micronized products and certain other products during and following the end of the period of enforcement discretion announced by the United States Food and Drug Administration ("FDA");
- expectations regarding future revenue growth, including product innovations, expansion into additional domestic and international markets, our product pipeline and the potential to increase our product offerings, and future research and development expenses;
- ongoing and future effects arising from the COVID-19 pandemic and the Company's plans to adhere to governmental recommendations with respect thereto;
- our expectations regarding market opportunities, expected growth in certain markets, and demographic and market trends.; and
- our expectations regarding our ability to resolve certain legal matters.

Forward-looking statements generally can be identified by words such as "expect," "will," "change," "intend," "seek," "target," "future," "plan," "continue," "potential," "possible," "could," "estimate," "may," "anticipate," "to be" and similar expressions.

These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company's operations and may cause the Company's actual actions, results, financial condition, performance or achievements to differ materially. Factors that may cause such a difference include, without limitation, those discussed under the heading "Risk Factors" in our most recent Form 10-Q and in our Form 10-K for the year ended December 31, 2019.

Unless required by law, the Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new information, the occurrence of subsequent events, a change in drcumstances or otherwise. Each forward-looking statement contained herein is specifically qualified in its entirety by the aforementioned factors.

Non-GAAP Financial Measures

This presentation includes non-GAAP financial measures to describe the Company's performance. Additional information and reconciliations of those measures to GAAP measures are provided in the appendix to this presentation beginning at slide 24.



MARKET LEADER WITH DIFFERENTIATED PLATFORM READY TO ACHIEVE LONG-TERM GROWTH

Leader in tissue-based products for advanced wound care

- 2 Strong & differentiated infrastructure to deliver growth
- **3** Versatile product offerings supported by robust clinical evidence
- 4 Underserved, growing market opportunity
- **5** Promising pipeline targets unmet needs in large markets
- 6 Experienced, new leadership team
 - Business now positioned for sustainable & profitable growth




PATIENTS ARE WHY WE ARE HERE.



WE HAVE AN OPPORTUNITY AND RESPONSIBILITY TO MAKE A DIFFERENCE FOR THESE PATIENTS. AND IN DOING SO, GROW A SUCCESSFUL AND MEANINGFUL HEALTHCARE COMPANY."

> TIMOTHY R. WRIGHT CHIEF EXECUTIVE OFFICER

MIMEDX IS A PIONEER IN PLACENTAL BIOLOGICS



Leading Brands in Existing Core Business Position Company to Capitalize on Late-stage Pipeline




LEADING PRODUCT PORTFOLIO POSITIONED FOR GROWTH

\$256M TTM Net Sales ¹ 2,000,000+ Allografts Distributed ⁴	84% Gross Margin ² <0.01% Reported Events ⁴	\$737M Market Cap ³ 75,000+ Placentas Recovered ⁴	WELCOME BACK TO NASDAQ MING-11/4/2020 MDXG NasdaqListed Nasdaq
30M with diabetes ⁵ (U.S.) 2.9M chronic wounds ⁶	Reimbursement coverage, U.S.: 300M+ lives	 Epific 5-year shelf life Room temp storag 300+ regulatory pr 	and the second sec
17.5M+ U.S. KOA patients ⁷	2M+ U.S. Patients treated for PF annually ⁸	1,000+ patients studied under IND clinical programs ⁹	10,000+ ft ² of ISO Class 7 clean room space

(1) Trailing twelve months period eded September 30, 2020, as reported in applicable SEC filings. (2) Represents GAAP gross margin for the trailing twelve months period ended September 30, 2020. (3) Based on closing stock price on November 18, 2020 (4) As of December 31, 2019; (5) Sen CK. Human Wounds and Its Burden: An Updated Compendium of Estimates. Adv Wound Care (New Rochelle). 2019;8(2):39-48. doi:10.1039/wound.2019.0946; (6) BioMed CPS SmartTrak; (7) Global Data Knee Reconstruction Data Model United States 2020 (8) Torg KB, Furia J. Economic burden of plantar fasciitis treatment in the United States. Am J Orthop (Belle Mead NJ). 2010;39(5):227-231; (9) MiMedx IND Clinical Trial Programs; Plantar Fasciitis Phase 2B: 147; Plantar Fasciitis Phase 3: 276; Knee Osteoarthritis Phase 2B: 430+; Achilles Tendonitis Phase 3: 158.





 Focus on clinical efficacy and cost effectiveness



7

UNLOCKING OUR POWERFUL PLATFORM FOR FUTURE GROWTH

MARKET-LEADING PLATFORM

- Universal tissue with broad applicability
- Rigorous quality manufacturing process with attractive gross margins
- Geographically distributed and scalable placenta donation & recovery network

BODY OF EVIDENCE

- 40+ clinical & scientific publications in peer-reviewed, indexed journals
- Best-in-class evidence recognized by AHRQ¹
- Robust publication strategy with accompanying medical education support

COMMERCIAL SCALE

- Experienced sales team with extensive reach & established customer relationships
- Reimbursement coverage of 300+ million lives (Medicare, Medicaid, Commercial)
- Current multi-year contracts, including commitment tier, with largest GPOs²

FINANCIAL STRENGTH


- Positioned to achieve **sustainable and profitable growth** in fast growing markets
- Strong balance sheet provides ability to pursue attractive growth opportunities
- Investing in promising late-stage pipeline for patients with unmet needs



WELL BALANCED ACROSS CARE SETTINGS

- Largest U.S. commercial payor will provide coverage for EpiFix[®] in the treatment of diabetic foot ulcers effective December 1, 2020
- Significant amount of revenue earned through **staggered**, **multiyear contracts** with GPOs, provide broad access to drive utilization
- Diversified care setting mix provides a stable platform for growth

Reimbursement coverage, U.S. **300M+** lives






FOUR KEY DRIVERS TO ACHIEVE CORE GROWTH

Existing Co	re Business	Portfolio I	xpansion			
ENHANCE PORTFOLIO VALUE	EXPAND THE MARKET	TARGET NEW BUSINESS	PURSUE INTERNATIONAL EXPANSION			
Maximize core businessEnhance sales force productivity and commercial analyticsHighlight clinical and economic value	<text><text><text></text></text></text>	<section-header><text><text></text></text></section-header>	<text><text><text></text></text></text>			



MAXIMIZING OPPORTUNITIES IN OUR CORE BUSINESS





LATE-STAGE PIPELINE AIMED AT SIZABLE MARKETS

Potential to address unmet patient needs as a platform technology across multiple markets

MUSCULOSKELETAL/SPORTS MEDICINE

Plantar Fasciitis			PHASE 3	1H 2022 Est. BLA filing
Achilles Tendonitis			PHASE 3	2H 2021 Est. BLA filing*
Knee Osteoarthritis		PHASE 2		1H 2024 Est. BLA filing

ADVANCED WOUND CARE

Chronic Wounds	PRE-CLINICAL	1H 2021 Est. IND/IDE filing
Surgical Incisions	PRE-CLINICAL	1H 2021 Est. IND/IDE filing
Soft Tissue Defects	PRE-CLINICAL	1H 2021 Est. IND/IDE filing

* Dependent on data readout

According to recently updated FDA guidance, FDA generally intends to exercise enforcement discretion through May 31, 2021, with respect to the IND and the premarket approval requirements for certain HCT/Ps, provided that use of the HCT/P does not raise reported safety concerns or potential significant safety concerns, Timeline represents current plans and estimates only. Actual results and timing may differ materially. There can be no assurance that clinical trials are conducted or completed on schedule, that trial results are favorable, or that we obtain regulatory approval for our products and indications



FINANCIAL STRENGTH FORTIFIES SUSTAINABLE AND PROFITABLE GROWTH

Adjusted Net Sales¹

Adjusted Gross Margin¹

83.8%

Net Loss (TTM)

Includes:

- \$12.1M benefit from Revenue Transition
- \$59.2M charge for Investigation, Restatement and Related Expenses

Adjusted Net Sales²

Adjusted EBITDA as % of

3Q 2019 4Q 2019 1Q 2020 2Q 2020 3Q 2020

Adj. Free Cash Flow³



Inventory levels provide sufficient supply

(1) Trailing twelve months period ended September 30, 2020. Adjusted Net Sales and Adjusted Gross Margin are non-GAAP measurements and exclude impact of Revenue Transition amounts; Refer to slide 3 for the respective GAAP amount and to slide 24 for more information. (2) Calculated on a trailing twelve-month basis for each period. Adjusted Net Sales and Adjusted EBITDA are non-GAAP measurements. Refer to slide 24 for more information. (3) Adjusted Free Cash Flow is calculated as Adjusted EBITDA less capital expenditures and patent application costs; Refer to slide 24 for more information.



CONTINUED PROGRESS TO RESOLVE REMAINING LEGAL CONTINGENCIES



Current spend relates to legal matters involving the company (fees and resolution) and indemnification costs for former officers and directors

- Company has utilized some of the applicable Directors & Officers insurance, and has some remaining coverage available
- 12 of 15 material litigation matters disclosed in 2019 Form 10-K now resolved; appendix lists specific cases
- Securities class action matter remains outstanding; mediation scheduled for December



RECENT FINANCINGS AND NASDAQ RELISTING PROVIDE FINANCIAL FLEXIBILITY

Financing transactions¹ provide ability to:


- Prioritize investment in growth drivers
- Pursue attractive growth opportunities
- Stabilize business

Issued \$100 million in convertible preferred stock

- Initial holders are affiliates of EW Healthcare Partners (90%) and Hayfin Capital Management (10%)
- Two board members: Bill Hawkins and Marty Sutter

Entered into \$75 million loan facility

- Term loan of \$50 million
- Delayed draw of \$25 million available through June 2021
- Counterparties are affiliates of Hayfin Capital Management





MARKET LEADER WITH DIFFERENTIATED PLATFORM READY TO ACHIEVE LONG-TERM GROWTH

Leader in tissue-based products for advanced wound care

- 2 Strong & differentiated infrastructure to deliver growth
- **3** Versatile product offerings supported by robust clinical evidence
- 4 Underserved, growing market opportunity
- **5** Promising pipeline targets unmet needs in large markets
- 6 Experienced, new leadership team
 - Business now positioned for sustainable & profitable growth



QUESTION & ANSWER SESSION



APPENDIX



CLINICAL EVIDENCE DEMONSTRATES DIFFERENTIATION & SUPPORTS REIMBURSEMENT

BEST-IN-CLASS CLINICAL EVIDENCE

- Statistically significant results*
- Randomized controlled trials across multiple applications
- Head-to-head study results demonstrate superior clinical outcomes & substantially lower cost-toclosure compared to Apligraf[®]
- Studies demonstrate low Risk-of-Bias*

STUDY	RESULT
EpiFix DFU RCT Study ¹	Complete Wound Closure: 92% at 6 weeks (p=.001)
EpiFix DFU RCT – Weekly vs. Biweekly Application ²	Overall Complete Wound Closure: 92.5% healing in 12 weeks Mean time to Healing: – Weekly applications: 2.4 weeks – Biweekly applications: 4.1 weeks
EpiFix DFU RCT – EpiFix vs. Apligraf® vs. SOC Study ^{3,4}	Complete Wound Closure: 85% at 4 weeks 95% at 6 weeks Cost Effectiveness: • Subjects receiving EpiFix used 58% fewer grafts • Median cost of graft material for EpiFix was 83% less than Apligraf®
EpiFix DFU Multicenter RCT ⁵	Complete Wound Closure: 81% at 12 weeks (PP: Per-Protocol) 70% at 12 weeks (ITT: Intent-to-Treat)
EpiFix VLU Surrogate Endpoint Study ⁶	62% of patients achieved ≥ 40% wound closure at 4 weeks
EpiFix VLU Multicenter RCT ⁷	Complete Wound Closure: 60% at 12 weeks 71% at 16 weeks
EpiCord Multicenter RCT ⁸	Complete Wound Closure: 81% at 12 weeks (PP: Per-Protocol) 70% at 12 weeks (ITT: Intent-to-Treat)

VALIDATION OF DATA IN RECENT AHRQ^{*} REPORT

"intended to help health care **decision makers** patients and clinicians, health system leaders, and policymakers, among others — make **wellinformed decisions** and thereby improve the quality of health care services"



EXPERIENCED LEADERSHIP TEAM



PETE CARLSON Chief Financial Officer





BUTCH HULSE General Counsel & Secretary

Dykema



ROHIT KASHYAP, PhD Chief Commercial Officer





ROBERT STEIN, MD, PhD EVP, Research & Development





SVP, Operations & Procurement



Johnson 4 Johnson





TIMOTHY R. WRIGHT Chief Executive Officer





MARK GRAVES Chief Compliance Officer





STAN MICEK SVP, Business Development

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER





MARK ROGERS VP, Global Quality Assurance & Regulatory It surgical BIOMINETIC FILE BIOMINETIC FILE BIOMINETIC

MATERIAL LITIGATION CLOSURE UPDATE

12 of 15 "Material Litigation" matters disclosed in 2019 Form 10-K now resolved

Matters Resolved in Last 16 Months

Matter	Type of Matter	Timing of Resolution
Shareholder Derivative Litigation	Derivative Claims for Breach of Fiduciary Duty	Q2 2020
Annual Meeting Litigation	Two Cases to Compel Shareholder Meetings	Q2/Q3 2019
S.E.C. Civil Enforcement	Civil Enforcement	Q4 2019
V.A./DOJ Pricing Practices	<i>Qui Tam</i> Action	Q2 2020
NuTech	Patent	Q3 2020
Osiris	Breach of Contract Trade Secret Theft	Q3 2020
OSHA	Retaliation	Q2 2020
Kruchoski	Retaliation	Q3 2019
Fox	Retaliation	Q4 2019
Scott	Retaliation/Gender Discrimination	Q4 2019
MDNC	Healthcare Industry Compliance Investigation	Q4 2020 ¹
PAN	<i>Qui Tam</i> Action	Q4 2020 ¹


Matters Pending

Matter	Type of Matter
Securities Litigation	Civil Class Action
Sparrow	Defamation
Viceroy	Defamation



ADJUSTED NET SALES TRENDS REFLECT STABILIZATION POST COVID-19 DOWNTURN

Revenue presentation includes impact of 2019 transition in revenue recognition





SUMMARY BALANCE SHEETS

					Unaudited				
(\$ millions)	1Q19	2Q19	3Q19	4Q19	1Q20	2Q20	3Q20		
Assets									
Cash and Cash Equivalents	28.4	96.9	94.1	69.1	53.5	48.2	109.6		
Accounts Receivable, net	0.0	0.0	21.4	32.3	31.9	30.1	33.0		
Inventory, net	16.4	15.0	12.0	9.1	9.2	10.6	11.0		
Other Current Assets	12.4	10.6	6.5	12.7	21.2	18.7	17.9		
Total Current Assets	57.2	122.5	134.0	123.2	115.9	107.6	171.5		
Property and Equipment	16.4	14.7	13.2	12.3	11.8	10.8	10.3		
Other Assets	33.9	33.1	32.1	31.6	31.2	32.5	31.5		
Total Assets	107.4	170.3	179.3	167.2	158.9	150.9	213.3		
Liabilities and Stockholders' Equity									
Current Liabilities	64.3	78.1	73.4	67.3	63.7	63.7	57.3		
Long Term Debt, net	0.0	63.1	62.2	61.9	61.6	61.5	47.6		
Other Liabilities	4.7	4.5	4.2	3.5	3.2	2.9	4.4		
Total Liabilities	69.1	145.6	139.7	132.8	128.6	128.1	109.3		
Convertible Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	91.1		
Stockholders' Equity	38.4	24.7	39.6	34.4	30.3	22.9	12.9		
Total Liabilities and Stockholders' Equity	107.4	170.3	179.3	167.2	158.9	150.9	213.3		



SUMMARY INCOME STATEMENTS

					Unaudited				
(\$ millions)	1Q19	2Q19	3Q19	4Q19	1Q20	2Q20	3Q20		
Net Sales	66.6	67.4	88.9	76.4	61.7	53.6	64.3		
Cost of Sales	7.4	9.7	13.2	12.7	10.0	8.2	10.3		
Gross Profit	59.1	57.7	75.7	63.7	51.7	45.4	54.0		
Research & Development	2.9	2.8	2.7	2.7	2.7	2.3	3.4		
Selling, General, and Administrative	50.9	50.6	51.3	45.4	46.9	37.3	48.0		
Investigation, Restatement, and Related	18.1	21.0	7.2	20.1	15.6	11.4	12.0		
Amortization of Intangible Assets	0.2	0.3	0.3	0.3	0.3	0.3	0.3		
Impairment of Intangible Assets	0.4	0.0	0.0	0.0	0.0	0.0	0.0		
Operating (Loss) Income	(13.4)	(17.1)	14.2	(4.9)	(13.7)	(5.9)	(9.7)		
Loss on extinguishment of debt	0.0	0.0	0.0	0.0	0.0	0.0	(8.2)		
Interest Expense, net	0.2	(0.3)	(2.3)	(2.4)	(2.4)	(2.6)	(1.5)		
Other (Expense) Income, net	(0.0)	0.2	0.1	0.0	0.0	(0.0)	0.0		
Pretax (Loss) Income	(13.2)	(17.2)	12.1	(7.3)	(16.1)	(8.4)	(19.4)		
Income Tax Provision (Expense) Benefit	(0.0)	(0.0)	0.3	(0.2)	11.3	(0.0)	(0.0)		
Net (Loss) Income	(13.3)	(17.2)	12.4	(7.5)	(4.8)	(8.5)	(19.4)		



SUMMARY CASH FLOW STATEMENTS

(\$ millions)	1Q19	2Q19	3Q19	4Q19	1Q20	2Q20	3Q20
Net (Loss) Income	(13.3)	(17.2)	12.4	(7.5)	(4.8)	(8.5)	(19.4)
Effect of Change in Revenue Recognition	0.0	0.0	(17.4)	0.0	0.0	0.0	0.0
Share-Based Compensation	3.0	3.5	2.7	2.9	3.3	4.4	3.7
Depreciation	1.7	1.6	1.6	1.6	1.5	1.4	1.5
Other Non-Cash Effects	1.8	0.9	1.1	1.2	1.2	1.3	9.5
Changes in Assets	(0.0)	3.6	1.3	(14.2)	(8.2)	2.9	(1.8)
Changes in Liabilities	(8.4)	9.7	(4.9)	(7.0)	(5.3)	(4.7)	1.9
Net Cash Flows Used in Operating Activities	(15.3)	2.1	(3.2)	(23.1)	(12.3)	(3.1)	(4.6)
Purchases of Property and Equipment	(0.6)	(0.3)	(0.2)	(0.7)	(1.0)	(0.4)	(0.7)
Principal Payments from Note Receivable	0.4	0.0	2.3	0.0	0.0	0.0	0.0
Patent Application Costs	(0.2)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)	(0.0)
Net Cash Flows Used in Investing Activities	(0.4)	(0.3)	2.1	(0.8)	(1.1)	(0.5)	(0.7)
Preferred Stock Net Proceeds	0.0	0.0	0.0	0.0	0.0	0.0	93.4
Proceeds from Term Loan	0.0	72.8	0.0	0.0	0.0	10.0	49.5
Repayment of Term Loan	0.0	0.0	(0.9)	(0.9)	(0.9)	(10.9)	(72.0)
Prepayment Premium on Term Loan	0.0	0.0	0.0	0.0	0.0	0.0	(1.4)
Deferred Financing Cost	0.0	(6.0)	(0.6)	(0.0)	0.0	(0.0)	(2.8)
Stock Repurchased for Tax Withholdings on Vesting of Restricted Stock	(1.0)	(0.1)	(0.2)	(0.2)	(1.5)	(0.8)	(O.1)
Proceeds from Exercise of Stock Options	0.0	0.1	0.0	0.0	0.3	0.0	0.1
Net Cash Flows Used in Financing Activities	(1.0)	66.7	(1.7)	(1.1)	(2.2)	(1.8)	66.7
Beginning Cash Balance	45.1	28.4	96.9	94.1	69.1	53.5	48.2
Change in Cash	(16.7)	68.5	(2.8)	(25.1)	(15.5)	(5.3)	61.4
Ending Cash Balance	28.4	96.9	94.1	69.1	53.5	48.2	109.6



NON-GAAP METRICS RECONCILIATION

									Unaudited					
(\$ millions)	1	IQ19		2Q19		3Q19	2	4Q19	1	IQ20	2	Q20	3	3Q20
Net Sales – Reported	\$	66.6	\$	67.4	\$	88.9	\$	76.4	\$	61.7	\$	53.6	\$	64.3
Less: Revenue Transition Impact ¹		_		_		21.5		8.2		4.5		1.7		1.0
Adjusted Net Sales	\$	66.6	\$	67.4	\$	67.3	\$	68.2	\$	57.2	\$	51.9	\$	63.3
Gross Profit	\$	59.1	\$	57.7	\$	75.7	\$	63.7	\$	51.7	\$	45.4	\$	54.0
Less: Revenue Transition Impact ¹		_		_		18.6		7.1		3.9		1.5		0.9
Adjusted Gross Profit	\$	59.1	\$	57.7	\$	57.1	\$	56.6	\$	47.8	\$	44.0	\$	53.1
Adjusted Gross Margin		88.7 %		85.6%		84.8%		83.0%		83.6 %		84.8 %		83.9 %
Adjusted EBITDA	\$	10.9	\$	9.5	\$	7.6	\$	14.1	\$	3.1	\$	10.2	\$	6.9
Less: Capital Expenditures	+	(0.6)	· ·	(0.3)	+	(0.2)	Ŧ	(0.7)	+	(1.0)	+	(0.4)	+	(0.7)
Less: Patent Application Costs		(0.2)		(0.1)		(0.1)		(0.1)		(0.1)		(0.1)		(0.0)
Adjusted Free Cash Flow	\$	10.1	\$	9.1	\$	7.3	\$	13.3	\$	2.0	\$	9.7	\$	6.2

(1) Impact of revenue transition includes the Transition Adjustment during 3Q2019 and cash collected in 4Q2019, 1Q2020, 2Q2020, and 3Q2020 related to the remaining contracts. For a discussion of the revenue transition and the defined terms, refer to Item 8, Notes to the Consolidated Financial Statements in the MiMedx Group, Inc. Form 10-K for the year ended December 31, 2019, and the respective Form 10-Qs for the noted quarterly periods.



ADJUSTED EBITDA RECONCILIATION

(\$ millions)	4Q19	1Q20	2Q20	3Q20
Net Loss	(7.5)	(4.8)	(8.5)	(19.4)
Depreciation & Amortization	1.8	1.8	1.7	1.8
Interest Expense	2.4	2.4	2.6	1.5
Loss on Extinguishment of Debt	0.0	0.0	0.0	8.2
Income Tax	0.2	(11.3)	0.0	0.0
EBITDA	(3.0)	(12.0)	(4.2)	(7.9)
Investigation, Restatement & Other	20.1	15.6	11.4	12.0
Revenue Transition	(5.9)	(3.9)	(1.5)	(0.9)
Share-Based Compensation	2.9	3.3	4.4	3.7
Adjusted EBITDA ¹	14.1	3.1	10.2	6.9

Investigation, Restatement & Other:

- Audit Committee Investigation completed in 2Q19
- Restatement activities completed in 2Q20
- Going forward, remainder is legal costs for Company matters, resolution costs for Company matters, and indemnification costs under agreements with former officers and directors

Revenue transition excludes gross profit impact of shipments prior to 10/1/19 (see slide 24)

